Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Y-mAbs Therapeutics

Explore full profile

Clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients

New York City, United StatesFounded 2014Biotech & Life Sciences
Valuation $332M Market cap · 2025
Revenue $88M Latest reported FY
Total funding $100–500M Disclosed equity funding

About Y-mAbs Therapeutics

Y-mAbs Therapeutics was founded in 2015 by Thomas Gad, with a mission to develop innovative cancer treatments. The company focuses on creating antibody-based therapies, particularly targeting pediatric oncology.

Read full description

In its early years, Y-mAbs concentrated on developing a robust pipeline of drug candidates. Their dedication to addressing unmet medical needs in cancer treatment quickly garnered attention in the biotech community.

A significant milestone for Y-mAbs came in September 2018, when the company went public on the NASDAQ under the ticker YMAB. The IPO was a pivotal moment, providing the necessary capital to advance their clinical trials and expand their research capabilities.

Y-mAbs has since made notable progress, particularly with its lead product candidates, which have shown promise in treating neuroblastoma, a rare pediatric cancer. The company's commitment to innovation and patient care continues to drive its research and development efforts.

Today, Y-mAbs stands as a testament to the impact of focused scientific research and the potential of antibody-based therapies in transforming cancer treatment. The journey of Y-mAbs Therapeutics highlights the importance of perseverance and innovation in the biopharmaceutical industry.

Source: Dealroom company data

At a glance

Founded
2014
Headquarters
New York City, United States
Listing
IPO 2018
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierColt$25–100M revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later3 investors entered at this stage

  • Sofinnova Investments
  • Scopia Capital
  • Memorial Sloan - Kettering Cancer Center

Talent

Book a demo to see the people
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States59.3%
🇩🇰 Denmark40.7%
2 countries shown
Web traffic by country
4.9K monthly visits
across markets
🇺🇸 United States65.3%
🇮🇳 India24.5%
🇯🇵 Japan10.2%
Top 3 markets shown

Patents

Estimated portfolio value
$378k

6 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Y-mAbs Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Y-mAbs Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles